公告显示，RAY1225注射液是创新结构多肽药物，具有GLP-1受体和GIP受体双重激动活性，得益于优 异的药代动力学特性，具备每两周注射一次的长效药物潜力。 北京商报讯（记者 丁宁）12月4日晚间，众生药业（002317）发布公告称，公司控股子公司广东众生睿 创生物科技有限公司自主研发的一类创新多肽药物 RAY1225 注射液新增适应症治疗"代谢相关脂肪性肝 炎"的药物临床试验获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意 RAY1225注射液新增适应症进行临床试验。 ...

| 恒生医疗保健业指数 港股创新药ETF | | --- | | (HSCICH) (513120) | | 周内涨跌 ↑ 3.64% 周内涨跌 ▲ 4.00% | | - A股当周涨跌幅 - | | 海王生物 维康药业 | | 周内涨跌 ↑ 38.21% [周内涨跌 - 6.46% | | - 港股当周涨跌幅 - | | 康方生物 博安生物 | | 周内涨跌 ↑ 14.86% (周内涨跌) 2.08% | | 聚焦同分 | | 热门赛道 众生药业儿童用抗甲流药物昂拉地韦 | | 颗粒Ⅲ期试验开始入组 | | 一周热股 海王生物上涨近四成,康方生物领跑 | | 港股创新药 | | 前沿动向 凌科药业拟赴港IPO 核心在研产品面 | | 临同类激烈竞争，已将商业化权益授 | | 予先声药业 | | 《掘金创新药》栏目由每日经济新闻推出，每周一期 | | --- | | 解读新药研发进展与趋势 剖析产品竞争力与市场前景 | | 洞察医药资本脉络 见证医药产业高质量发展 | | 数据来源：东方财富App、富途牛牛 | ""资本眼 每经记者｜金喆 每经编辑｜魏官红 一周行情 11月24日至11月28日，医药生物指数收 ...

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

Core Viewpoint - The Chinese traditional medicine sector is experiencing increased activity due to a surge in flu cases, with the Chinese Medicine ETF (560080) showing a slight decline but still attracting investor interest [1][9]. Market Performance - The Chinese Medicine ETF (560080) closed down 0.91% today, remaining in a consolidation phase, with a trading volume exceeding 84 million yuan, a 7% increase from the previous trading day [1]. - The ETF's closing premium rate was 0.06%, indicating ongoing investor attention, with two out of the last five days seeing inflows [1]. - The ETF's latest scale reached 2.598 billion yuan, leading its peers in the same category [1]. Stock Performance - Most constituent stocks of the Chinese Medicine ETF closed in the red, with notable declines including: - Pianzaihuang down 1.59% to 168.75 yuan, marking a five-year low [3]. - Yiling Pharmaceutical down over 3%, and Zhongsheng Pharmaceutical down over 2% [3]. - Conversely, stocks like Yunnan Baiyao and Jilin Aodong saw slight increases [3]. Valuation Metrics - As of December 3, the TTM price-to-earnings (PE) ratio for the ETF's index was 25.12, positioned at the 23.11% percentile over the past decade, suggesting that the index is cheaper than 76% of the time historically [5]. - The TTM PE is just 0.38 away from the calculated opportunity value, indicating a potential entry point for investors [5]. Historical Performance - The year-to-date return for the Chinese Medicine Index remains negative at -2.24%, with a decline of 8.13% projected for 2024 [7]. - The index has shown a pattern of consecutive declines, with four consecutive negative years if 2023 is considered a down year [7]. Demand Drivers - The recent flu outbreak has led to a significant increase in demand for respiratory medications, with flu cases reported rising by 53.8% compared to the previous week [9]. - The flu activity is at its highest level since 2022, which is expected to boost the demand for related medications [9]. Industry Outlook - Analysts from Zheshang Securities predict an inflection point for the Chinese medicine sector, suggesting that the sector will attract more investment due to its stable cash flow and lower volatility compared to other sectors [9]. - The industry is expected to see improved revenue and net profit growth in the second half of 2025, aided by reduced cost pressures from declining raw material prices [9].

每经头条（nbdtoutiao）——让"铁疙瘩"从数万米高空精准"踩刹车"，中国商业航天"降本复用"只差"最 后一公里"！朱雀之后，同行排队接力 每经AI快讯，众生药业（SZ 002317，收盘价：23元）12月4日晚间发布公告称，近日，广东众生药业股 份有限公司（以下简称"公司"）控股子公司广东众生睿创生物科技有限公司（以下简称"众生睿创"）自 主研发的一类创新多肽药物RAY1225注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物临床试验获得 国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意RAY1225注射液新增适应症进 行临床试验。 （记者 曾健辉） 2025年1至6月份，众生药业的营业收入构成为：医药制造占比96.13%，医药贸易占比3.29%，其他业务 占比0.58%。 截至发稿，众生药业市值为195亿元。 ...

代谢相关脂肪性肝炎(MASH)是由过量脂肪细胞引起的肝脏炎症，可导致进行性肝纤维化和肝硬化。 MASH的患者基数相当庞大，目前国内尚无专门获批用于治疗MASH的药物，存在巨大的未被满足的临 床治疗需求，因此开发有效的MASH治疗药物对改善患者的健康状况至关重要。 众生药业（002317）(002317.SZ)发布公告，近日，公司控股子公司广东众生睿创生物科技有限公司(以 下简称"众生睿创")自主研发的一类创新多肽药物RAY1225注射液新增适应症治疗"代谢相关脂肪性肝 炎"的药物临床试验获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意 RAY1225注射液新增适应症进行临床试验。 RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，具有GLP-1受体和 GIP受体双重激动活性，得益于优异的药代动力学特性，具备每两周注射一次的长效药物潜力。目前， RAY1225注射液用于治疗中国肥胖/超重患者的安全性和有效性的III期临床试验(REBUILDING-2研究)已 顺利启动并完成全部参与者入组工作;RAY1225注射液单药治疗2型糖尿病患者的安全性和有效性、安慰 剂对照的 ...

RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，具有GLP-1受体和 GIP受体双重激动活性，得益于优异的药代动力学特性，具备每两周注射一次的长效药物潜力。目前， RAY1225注射液用于治疗中国肥胖/超重患者的安全性和有效性的III期临床试验（REBUILDING-2研 究）已顺利启动并完成全部参与者入组工作；RAY1225注射液单药治疗2型糖尿病患者的安全性和有效 性、安慰剂对照的III期临床试验（SHINING-2）和RAY1225注射液与口服降糖药物联合治疗2型糖尿病 患者的安全性和有效性、司美格鲁肽注射液对照的III期临床试验（SHINING-3）两项降糖III期临床试验 目前参与者入组情况顺利。 格隆汇12月4日丨众生药业(002317.SZ)公布，公司控股子公司广东众生睿创生物科技有限公司（称"众 生睿创"）自主研发的一类创新多肽药物 RAY1225 注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物 临床试验获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意RAY1225注射液 新增适应症进行临床试验。 ...

RAY1225 能选择性结合并激活GLP-1受体和GIP受体，以葡萄糖依赖的方式促进胰岛素分泌和抑制胰高 血糖素从而控制血糖，同时抑制胃排空，抑制食欲，降低体重，降低外周胰岛素抵抗，改善肝脏脂肪变 性和气球样变等。RAY1225 的临床前研究结果表明，在MASH动物模型中RAY1225可改善的NAS评分 (评估肝脏炎症、坏死、纤维化等)、降低体重、改善脏体系数、糖脂代谢和肝脏脂肪水平，并呈现剂量 相关性，临床上有望用于MASH的治疗。 RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，具有GLP-1受体和 GIP受体双重激动活性，得益于优异的药代动力学特性，具备每两周注射一次的长效药物潜力。目前， RAY1225注射液用于治疗中国肥胖 /超重患者的安全性和有效性的III期临床试验(REBUILDING-2研究) 已顺利启动并完成全部参与者入组工作;RAY1225注射液单药治疗2型糖尿病患者的安全性和有效性、安 慰剂对照的III期临床试验(SHINING-2)和RAY1225注射液与口服降糖药物联合治疗2型糖尿病患者的安 全性和有效性、司美格鲁肽注射液对照的III期临床试验(SHIN ...

人民财讯12月4日电，众生药业（002317）12月4日公告，控股子公司广东众生睿创生物科技有限公司自 主研发的一类创新多肽药物RAY1225注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物临床试验获得 国家药监局批准，并收到《药物临床试验批准通知书》，同意RAY1225注射液新增适应症进行临床试 验。 ...

证券代码：002317 公告编号：2025-112 RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽 药物，具有GLP-1受体和GIP受体双重激动活性，得益于优异的药代动力学特性， 具备每两周注射一次的长效药物潜力。目前，RAY1225注射液用于治疗中国肥胖 /超重患者的安全性和有效性的III期临床试验（REBUILDING-2研究）已顺利启 第 1页 共 2页 广东众生药业股份有限公司 关于控股子公司收到一类创新药 RAY1225 注射液 新增适应症的药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众 生睿创生物科技有限公司（以下简称"众生睿创"）自主研发的一类创新多肽药 物 RAY1225 注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物临床试验获 得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意 RAY1225 注射液新增适应症进行临床试验。具体情况如下： 一、《药物临床试验批准通知书》基本情况 根据《中华人民共和国药品管 ...